Protocol
11-105
Full Title
Pilot Trial of Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
Purpose
Multiple myeloma is difficult to treat with chemotherapy alone. Sometimes higher doses of chemotherapy are used, but they can lower blood counts. Using a patient’s own cells (special cells called “stem cells”) to help increase blood counts after high doses of chemotherapy is called autologous stem cell transplantation (ASCT).
While advances in supportive care have improved the safety of ASCT, blood counts still decrease for a period of days after high doses of chemotherapy. During this time, patients are at greater risk for infections. Studies have shown that the faster blood counts recover after ASCT, the lower the risk of unwanted side effects.
Typically during an ASCT, a patient’s stem cells are returned to them all at once on a single day. In this study, researchers plan to see what happens when smaller amounts of a patient’s own stem cells are returned over several days. Some studies have suggested that this approach helps increase bone marrow activity and decrease the time it takes for blood counts to recover after ASCT.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of symptomatic multiple myeloma and be eligible to receive multiple high doses of chemotherapy.
- Patients must have initially responded to induction or salvage chemotherapy.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- Patients must be between the ages of 18 and 75 (inclusive).
For more information about this study and to inquire about eligibility, please contact Dr. Heather Landau at 212-639-8808.
Disease(s)
Hematology: Multiple Myeloma
Locations
ClinicalTrials.gov
Related Diseases
